NANOBIOTIX (NANO.PA)

FR0011341205 - Common Stock

4.454  -0.15 (-3.22%)

Fundamental Rating

2

Overall NANO gets a fundamental rating of 2 out of 10. We evaluated NANO against 74 industry peers in the Biotechnology industry. NANO may be in some trouble as it scores bad on both profitability and health. NANO is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

NANO had negative earnings in the past year.
In the past year NANO has reported a negative cash flow from operations.
NANO had negative earnings in each of the past 5 years.
In the past 5 years NANO always reported negative operating cash flow.

1.2 Ratios

NANO's Return On Assets of -42.28% is in line compared to the rest of the industry. NANO outperforms 42.25% of its industry peers.
Industry RankSector Rank
ROA -42.28%
ROE N/A
ROIC N/A
ROA(3y)-61.3%
ROA(5y)-59.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

NANO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

NANO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NANO has more shares outstanding
Compared to 5 years ago, NANO has more shares outstanding
NANO has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -3.49, we must say that NANO is in the distress zone and has some risk of bankruptcy.
NANO's Altman-Z score of -3.49 is on the low side compared to the rest of the industry. NANO is outperformed by 76.06% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.49
ROIC/WACCN/A
WACC9.19%

2.3 Liquidity

NANO has a Current Ratio of 1.75. This is a normal value and indicates that NANO is financially healthy and should not expect problems in meeting its short term obligations.
NANO has a Current ratio of 1.75. This is in the lower half of the industry: NANO underperforms 61.97% of its industry peers.
NANO has a Quick Ratio of 1.75. This is a normal value and indicates that NANO is financially healthy and should not expect problems in meeting its short term obligations.
NANO's Quick ratio of 1.75 is in line compared to the rest of the industry. NANO outperforms 43.66% of its industry peers.
Industry RankSector Rank
Current Ratio 1.75
Quick Ratio 1.75

More info and screens

5

3. Growth

3.1 Past

NANO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.74%, which is quite impressive.
The Revenue has been growing by 203.88% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)32.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.05%
Revenue 1Y (TTM)N/A
Revenue growth 3Y743.98%
Revenue growth 5Y203.88%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.22% on average over the next years. This is quite good.
The Revenue is expected to grow by 11.39% on average over the next years. This is quite good.
EPS Next Y17.52%
EPS Next 2Y1.66%
EPS Next 3Y13.81%
EPS Next 5Y8.22%
Revenue Next Year-15.57%
Revenue Next 2Y-27.85%
Revenue Next 3Y10.7%
Revenue Next 5Y11.39%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NANO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NANO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

NANO's earnings are expected to grow with 13.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.66%
EPS Next 3Y13.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NANO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NANOBIOTIX

EPA:NANO (9/6/2024, 7:00:00 PM)

4.454

-0.15 (-3.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap211.14M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.28%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.75
Quick Ratio 1.75
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)32.74%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y17.52%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3Y743.98%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y